OBIO
NASDAQ HealthcareOrchestra BioMed Holdings, Inc. - Ordinary Shares
Biotechnology
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
�� 市场数据
| 价格 | $6.08 |
|---|---|
| 成交量 | 1,137,342 |
| 市值 | 365.44M |
| 贝塔系数 | 0.530 |
| RSI（14日） | 61.7 |
| 200日均线 | $4.31 |
| 50日均线 | $4.65 |
| 52周最高 | $6.30 |
| 52周最低 | $2.20 |
| Forward P/E | -4.03 |
| Price / Book | 18.94 |
🎯 投资策略评分
OBIO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (88/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (5/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OBIO in your text
粘贴任何文章、记录或帖子 — 工具将提取 OBIO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.